Atlas Trials

A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma

Clinical trial NCT06500507 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06500507
Sponsor
Qilu Pharmaceutical Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed or Refractory Multiple Myeloma
Start date
2024-08-30
Primary completion
2026-03-31
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.